Lower dose cyclophosphamide with standard therapy for severe aplastic anemia
Part of Blood & lymphatic clinical trials.
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with severe or very severe aplastic anemia and have not started treatment yet.
- You must be at least 12 years old.
- You should not be able or willing to get a stem cell transplant.
- You must be generally well enough to carry out daily activities (ECOG score 0–2).
- You cannot have received more than 4 weeks of immune-suppressing drugs or platelet-boosting medicines before this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs to prepare older patients (40–60 years old) with severe aplastic anemia for a stem cell transplant from a half-matched donor. The goal is to make the transplant safer and more effective for this age group.
This Phase 2 study tests whether starting two oral medicines early—cyclosporine and eltrombopag—can improve severe aplastic anemia in people who have not had prior treatment for it. It may help your blood counts recover without needing stronger or earlier treatments.
This trial tests a new way to prepare the body for a donor stem cell transplant (allogeneic transplant) in people with severe aplastic anemia or other blood diseases. The goal is to make the transplant safer and more effective.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This trial tests whether adding a platelet-boosting medicine (rhTPO) to a standard immune-suppressing drug (cyclosporine) works better than cyclosporine alone for people with aplastic anemia who need regular blood transfusions. The goal is to improve blood counts and reduce the need for transfusions.
This trial tests a milder version of immunosuppressive therapy combined with hetrombopag (a drug that helps bone marrow make blood cells) in people aged 65 years and older with severe aplastic anemia. The goal is to see if this approach is both safer and effective for older patients.
Hear when a new Severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.